HOXA11 and cervical carcinoma: HOXA11 DNA methylation has already been identified as a potential biomarker in several cancers such as renal cell carcinoma, ovarian and cervical cancer, endometrial adenocarcinoma and non-small cell lung cancer [18,19,20].